Use of nonionic block copolymers in vaccines and therapeutics

被引:34
作者
Newman, MJ
Actor, JK
Balusubramanian, M
Jagannath, C
机构
[1] Vaxcel Inc, Norcross, GA 30092 USA
[2] Vetlife Inc, Norcross, GA 30092 USA
[3] Cytrx Corp, Norcross, GA 30092 USA
[4] Proceut Corp, Norcross, GA 30092 USA
来源
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS | 1998年 / 15卷 / 02期
关键词
poloxamer; nonionic block copolymer; adjuvant; vaccine; antibiotic;
D O I
10.1615/CritRevTherDrugCarrierSyst.v15.i2.10
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nonionic block copolymers synthesized from ethylene oxide and propylene oxide were developed specifically for use as surfactants. Because the sizes and relative positions of die hydrophobic polyoxypropylene (POP) and hydrophilic polyoxyethylene (POE) blocks can be altered during synthesis, copolymers with significantly different surfactant characteristics can be produced. Copolymers of this type are currently used as excipients in a wide variety of pharmaceutical products where they act as emulsifying, wetting, thickening, stabilizing, and dispersing agents. Copolymers with unique physicochemical properties have recently been developed through the use of new manufacturing and purification techniques, and these copolymers are being used as drug-active and drug-delivery components. In this review; we summarize the current status of these new copolymers in terms of research and product development. This includes die use of new, high molecular weight copolymers as vaccine adjuvants and as vaccine-delivery vehicles. The use of purified, pharmaceutical-grade copolymers as anti-infectives and as antibiotic-delivery systems for the treatment of established bacterial and viral infections is also reviewed. These novel uses for copolymers are significantly different from the excipient uses common to this type of product and demonstrate the widespread utility of synthetic surfactant polymers.
引用
收藏
页码:89 / 142
页数:54
相关论文
共 119 条
[1]   IMMUNOGENICITY OF SYNTHETIC TF-KLH (KEYHOLE LIMPET HEMOCYANIN) AND STN-KLH CONJUGATES IN COLORECTAL-CARCINOMA PATIENTS [J].
ADLURI, S ;
HELLING, F ;
OGATA, S ;
ZHANG, SL ;
ITZKOWITZ, SH ;
LLOYD, KO ;
LIVINGSTON, PO .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 41 (03) :185-192
[2]  
ALFONSO LCC, 1994, SCIENCE, V263, P235
[3]  
ALLISON AC, 1992, ADV EXP MED BIOL, V327, P133
[4]   LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS [J].
ALLISON, AC ;
GREGORIADIS, G .
NATURE, 1974, 252 (5480) :252-252
[5]   AN ADJUVANT FORMULATION THAT SELECTIVELY ELICITS THE FORMATION OF ANTIBODIES OF PROTECTIVE ISOTYPES AND OF CELL-MEDIATED-IMMUNITY [J].
ALLISON, AC ;
BYARS, NE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (02) :157-168
[6]   SYNTEX ADJUVANT FORMULATION [J].
ALLISON, AC ;
BYARS, NE .
RESEARCH IN IMMUNOLOGY, 1992, 143 (05) :519-525
[7]  
AREND WP, 1986, CLIN EXP IMMUNOL, V64, P656
[8]   DISTINCTIVE ADJUVANTICITY OF SYNTHETIC ANALOGS OF MYCOBACTERIAL WATER-SOLUBLE COMPONENTS [J].
AUDIBERT, F ;
CHEDID, L ;
LEFRANCIER, P ;
CHOAY, J .
CELLULAR IMMUNOLOGY, 1976, 21 (02) :243-249
[9]   A COMPARISON OF COMMERCIALLY AVAILABLE ADJUVANTS FOR USE IN RESEARCH [J].
BENNETT, B ;
CHECK, IJ ;
OLSEN, MR ;
HUNTER, RL .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 153 (1-2) :31-40
[10]   VACCINATING GUINEA-PIGS WITH RECOMBINANT GLYCOPROTEIN-D OF HERPES-SIMPLEX VIRUS IN AN EFFICACIOUS ADJUVANT FORMULATION ELICITS PROTECTION AGAINST VAGINAL INFECTION [J].
BYARS, NE ;
FRASERSMITH, EB ;
PECYK, RA ;
WELCH, M ;
NAKANO, G ;
BURKE, RL ;
HAYWARD, AR ;
ALLISON, AC .
VACCINE, 1994, 12 (03) :200-209